ArticleJACC. Advances2022

Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.

Mazen Hanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.